sites; foreign inspections conducted via:

• SFDA inspection team
• Reliance on EMA, US FDA, or WHO GMP certificates (case-by-case)

Deficiency Report: If observations are noted, a CAPA must be submitted within 30 calendar days

GMP Certificate Issuance: Valid for 3 years with conditions on compliance maintenance

UAE and Gulf Countries – GHC Mutual Recognition Framework

• GHC member states include UAE, Bahrain, Kuwait, Oman, Qatar, and Saudi Arabia
• UAE MOHAP accepts GMP certificates from:
  • SFDA, EMA, WHO, TGA
  • And sometimes PIC/S-compliant agencies
• GMP inspections are carried out for:
  • New product registrations
  • License renewals and pharmacovigilance concerns
• Common submission requirements:
  • Validation reports
  • Stability data and shelf-life justification
  • Batch release records
  • QA and QP certification documentation

Egypt (EDA) – National Inspection Requirements

• Egyptian Drug Authority enforces strict GMP oversight for both domestic and imported products
• Foreign manufacturers must submit:
  • Valid GMP certificate from a recognized authority
  • Full manufacturing dossier with site history
  • Import license and registration documentation
• EDA reserves the right to conduct:
  • On-site GMP audits for high-risk products
  • Random audits triggered by complaints or recall reports
• Certification is typically valid for 2–3 years with interim assessments

Jordan, Morocco, Tunisia – Localized GMP Frameworks

• Jordan (JFDA):
  • Follows WHO GMP but requires country-specific dossier structure
  • GMP inspections are required for:
    • New marketing authorizations
    • Import approvals
    • Tech transfer projects
• Morocco:
  • Inspections are mandatory for local sites and may be requested for imports
  • WHO GMP principles are applied but tailored with national health policy constraints
• Tunisia:
  • Requires bilingual documentation (Arabic + French or English)
  • Facility layout and HVAC validation are critical focus areas

Challenges in MENA GMP Certification Processes

• Lack of full harmonization across countries increases dossier customization burden
• Variations in inspection frequency, audit checklists, and CAPA expectations
• Language translation and localized regulatory interpretations may delay approvals
• Dependence on manual processes and paper-based submissions in some countries

Best Practices for Navigating MENA GMP Certification

1. Maintain a regulatory intelligence matrix for each MENA country
2. Engage regional consultants with experience in local GMP nuances
3. Prepare bilingual inspection documentation and train site staff accordingly
4. Conduct internal audits using WHO TRS, SFDA, and GHC inspection templates
5. Track renewal timelines and proactively schedule re-inspections

Digital Trends and Regional Harmonization Efforts

• Saudi Arabia and UAE are advancing e-submission platforms and digital GMP dashboards
• GHC continues to expand reliance models for generic and biologic drugs
• WHO is supporting joint inspections in selected MENA countries through PQP initiatives
• Increased regional participation in global programs such as PIC/S and ICMRA is expected

Conclusion

The MENA region presents a diverse and dynamic regulatory environment for pharmaceutical GMP certification. While some countries are deeply aligned with international standards, others maintain distinct local processes that require careful navigation. By understanding the certification structures, inspection triggers, and regulatory expectations of each country, pharmaceutical companies can streamline market access, avoid compliance pitfalls, and strengthen their reputation in the region.